Literature DB >> 23272791

Under-representation of older adults in pharmacokinetic and pharmacodynamic studies: a solvable problem?

Arduino A Mangoni1, Paul A F Jansen, Stephen H D Jackson.   

Abstract

The impact of advancing age, with or without the presence of structural and/or functional organ impairment, on the disposition and effects of drugs, demands adequate representation of older adults in pharmacokinetic and pharmacodynamic studies. Currently, however, this group remains poorly represented both in pre- and post-marketing studies. This review discusses recent data on the participation of older adults in pharmacokinetic/pharmacodynamic studies using established databases, the potential barriers to study recruitment and retention and possible strategies to enhance participation in this group. The article also provides a critical appraisal of current regulatory documents on the conduct of such studies.

Mesh:

Year:  2013        PMID: 23272791     DOI: 10.1586/ecp.12.75

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  9 in total

Review 1.  Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases.

Authors:  Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson
Journal:  Biol Psychiatry       Date:  2019-04-17       Impact factor: 13.382

Review 2.  Incorporating pharmacokinetic data into personalised prescribing for older people: challenges and opportunities.

Authors:  Arduino A Mangoni; Elzbieta A Jarmuzewska
Journal:  Eur Geriatr Med       Date:  2021-01-08       Impact factor: 1.710

3.  Geriatric medicine in an aging society: up for a challenge?

Authors:  Arduino A Mangoni
Journal:  Front Med (Lausanne)       Date:  2014-04-29

4.  Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial.

Authors:  Jean T Coulibaly; Gordana Panic; Kigbafori D Silué; Jana Kovač; Jan Hattendorf; Jennifer Keiser
Journal:  Lancet Glob Health       Date:  2017-07       Impact factor: 26.763

5.  A novel simulation-based approach to training for recruitment of older adults to clinical trials.

Authors:  Harriet Fisher; Sondra Zabar; Joshua Chodosh; Aisha Langford; Chau Trinh-Shevrin; Scott Sherman; Lisa Altshuler
Journal:  BMC Med Res Methodol       Date:  2022-06-28       Impact factor: 4.612

Review 6.  Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response.

Authors:  Annette S Gross; Anya C Harry; Christine S Clifton; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2022-02-17       Impact factor: 3.716

7.  Attitudes of ambulatory care older Nepalese patients towards deprescribing and predictors of their willingness to deprescribe.

Authors:  Shakti Shrestha; Roshan Giri; Hari Prasad Sapkota; Siddhartha Sharma Danai; Ahsan Saleem; Shreeshab Devkota; Sagar Shrestha; Bhojraj Adhikari; Arjun Poudel
Journal:  Ther Adv Drug Saf       Date:  2021-06-17

Review 8.  Optimal management of ADHD in older adults.

Authors:  Terje Torgersen; Bjorn Gjervan; Michael B Lensing; Kirsten Rasmussen
Journal:  Neuropsychiatr Dis Treat       Date:  2016-01-08       Impact factor: 2.570

9.  Under-representation of elderly in clinical trials: An analysis of the initial approval documents in the Food and Drug Administration database.

Authors:  Rikje Ruiter; Jacobus Burggraaf; Robert Rissmann
Journal:  Br J Clin Pharmacol       Date:  2019-02-23       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.